Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma
Nadia Barahmani N et al. – A study of whether glutathione S-transferases (GSTs) polymorphisms are in part responsible for individual differences in toxicity and responses in pediatric medulloblastoma concludes that GSTM1 and GSTT1 polymorphisms may predict adverse events, including cognitive impairment after therapy, in pts with medulloblastoma.
Methods- Study of the relationship between GSTM1 and GSTT1 polymorphisms and survival and toxicity in 42 children with medulloblastoma
- Kaplan-Meier analyses to determine if GST polymorphisms related to progression-free survival
- Logistic regression to explore associations between GST polymorphisms and occurrence of ≥grade 3 (Gr 3) myelosuppression, ototoxicity, nephrotoxicity, neurotoxicity, and intellectual impairment.
Results- Pts with ≥1 null genotype had a 4.3, 3.7, and 6.4 times increased risk for any Gr 3 toxicity, any Gr 3 toxicity excluding peripheral neuropathy, and any Gr 3 toxicity requiring omission or cessation of chemotherapy, respectively
- Pts with ≥1 null genotype had an average 27.2, 29, and 21.7 lower full-scale, performance, and verbal intelligence quotient scores, respectively
[more...]
|
|
|
